Advertisement

Topics

Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market

09:01 EDT 9 Aug 2017 | SCRIP

The Danish group expects its experimental GLP-1 semaglutide to prove so effective and safe in fighting obesity that it will...

      

Related Stories

 

Original Article: Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market

NEXT ARTICLE

More From BioPortfolio on "Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market"

Quick Search
Advertisement
 

Relevant Topic

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...